Ellen M. van der Aar

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 232 citations · Full text

Fibrosis, Novel Autotaxin Inhibitor, Allergy +7

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology · 2013 · 225 citations · Full text

Immunology, Immunologic Mechanism, Immune Dysregulation +19

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

Christel Menet, Stephen R. Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry · 2014 · 116 citations · Full text

Drug Target, Hit Identification, Janus Kinases +26

Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic

Mathieu Pizzonero, Sonia Dupont, Marielle Babel et al. · Journal of Medicinal Chemistry · 2014 · 107 citations · Full text

Inflammation, From Hit, Medicinal Chemistry +15

Structure-activity relationships for chemical and glutathione S-transferase-catalysed glutathione conjugation reactions of a series of 2-substituted 1-chloro-4-nitrobenzenes

Ellen M. van der Aar, Tialda Bouwman, Jan N. M. Commandeur et al. · Biochemical Journal · 1996 · 20 citations · Full text

Halogenation, Charge Distributions, Chemical Transformation +13